Irina Iaru

Dr. Irina Iaru


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
LDLiliana-Elisabeta David
Liliana-Elisabeta David
Anca Monica BrataAnca Monica Brata
Anca Monica Brata
Cristina MogosanCristina Mogosan
Cristina Mogosan
CPCristina Pop
Cristina Pop
ZCZoltan Czako
Zoltan Czako
PSPopa Stefan-Lucian
Popa Stefan-Lucian
Over recent decades, a new antibiotic crisis has been unfolding due to a decreased research in this domain, a low return of investment for the companies that developed the drug, a lengthy and difficult research process, a low success rate for candidate molecules, an increased use of antibiotics in farms and an overall inappropriate use of antibiotics. This has led to a series of pathogens developing antibiotic resistance, which poses severe threats to public health systems while also driving up the costs of hospitalization and treatment. Moreover, without proper action and collaboration between academic and health institutions, a catastrophic trend might develop, with the possibility of returning to a pre-antibiotic era. Nevertheless, new emerging AI-based technologies have started to enter the field of antibiotic and drug development, offering a new perspective to an ever-growing problem. Cheaper and faster research can be achieved through algorithms that identify hit compounds, thereby further accelerating the development of new antibiotics, which represents a vital step in solving the current antibiotic crisis. The aim of this review is to provide an extended overview of the current artificial intelligence-based technologies that are used for antibiotic discovery, together with their technological and economic impact on the industrial sector.

27 April 2021 in Plants
Verified
Journal Article
Open access
PDF file
GBGeorgeta Balica
Georgeta Balica
Oliviu VostinaruOliviu Vostinaru
Oliviu Vostinaru
CSCristina Stefanescu
Cristina Stefanescu
Cristina MogosanCristina Mogosan
Cristina Mogosan
IIIrina Iaru
Irina Iaru
Carmen Elena PopCarmen Elena Pop
Carmen Elena Pop
Propolis is a resinous mixture with a complex chemical composition, produced by honeybees and stingless bees from a variety of vegetal sources. In the last decades, propolis was extensively researched, multiple studies confirming its anti-inflammatory, antioxidant, antimicrobial, and wound-healing properties. More recently, due to an exponential increase in the number of patients with metabolic diseases, there is also a growing interest in the study of antidiabetic, antihyperlipidemic, and anti-obesity effects of propolis. The aim of this review was to evaluate the potential role of propolis in the prevention and treatment of metabolic diseases like diabetes mellitus, dyslipidemia, and obesity. The preclinical in vivo and in vitro pharmacological models investigating antidiabetic, antihyperlipidemic, and anti-obesity effects of propolis were reviewed with a focus on the putative mechanisms of actions of several chemical constituents. Additionally, the available clinical studies and an evaluation of the safety profile of propolis were also presented.

1 July 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
CPCristina Pop
Cristina Pop
ACAnamaria Cristina
Anamaria Cristina
IIIrina Iaru
Irina Iaru
SPStefan L. Popa
Stefan L. Popa
CMCristina Mogoșan
Cristina Mogoșan
Background: Pharmacogenetics (PGx) is an important component of personalized medicine that has the potential to improve medicines’ effectiveness and safety. However, despite progress in technology and availability, PGx testing application into patient-care in Eastern Europe countries, has been slow.Objectives: Our aim was to describe knowledge and attitudes of Romanian pharmacists concerning PGx, and identify potential factors limiting PGx implementation.Method: An anonymous, web-based questionnaire was distributed to Romanian pharmacists registered in the National Pharmacists’ Association (NPA) via an official e-mail sent by NPA representatives.Results: A total of 1,058 pharmacists completed the questionnaires, resulting in a response rate of 7.6%. Pharmacists were predominantly female (90.1%), younger than 49 years (87.5%) and mostly worked in community pharmacies (80.2%). Most pharmacists (64.8%) had a knowledge score between 30 and 49 points out of 60, and (75.4%) had attitude scores between 9 and 7 out of 10. Attitude and knowledge scores positively correlated.Conclusion: Despite performing fairly well on general questions regarding PGx, Romanian pharmacists may lack in-depth knowledge, which can affect their readiness to discuss PGx information with patients or other healthcare professionals. High pricing was considered an important impediment in PGx implementation.

27 March 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
IIIrina Iaru
Irina Iaru
CBCamelia Bucsa
Camelia Bucsa
AFAndreea Farcas
Andreea Farcas
CPCristina Pop
Cristina Pop
ACAnamaria Cristina
Anamaria Cristina
CMCristina Mogosan
Cristina Mogosan
Background: Mental disorders can have a significant impact on patients’ life, including economic, social and individual consequences, and psychotropic medication is essential to treat these conditions. Psychotropic drug utilization studies contribute to a clearer picture of the management of these conditions. Data published from Romania on this topic is limited. The present study aims to characterize the utilization patterns of anxiolytics, antidepressants (ADs), and antipsychotics (APs) in Romania during 1998–2018.Methods: Drug utilization data were provided by Management Center for Documentation, Information and Marketing (CEGEDIM) Romania and quantitative data for each psychotropic medicine were converted to total defined daily doses (DDDs) and to DDD/1000inhabitants/day (DDD/TID). The total use of medicines in DDD/TID was computed in order to obtain the drug utilization 90% (DU90%) segment.Results: An increasing trend in total utilization of psychotropic medicines in Romania started in 2004. Anxiolytics use was predominant until 2013 and the yearly anxiolytic use over the entire study period remained between 10 and 15 DDD/TID. Diazepam lost popularity over time in detriment of the utilization of other anxiolytic benzodiazepines, such as alprazolam and lorazepam. ADs utilization markedly increased during the study period (the average annual growth rate was 13.66% starting 1999). Selective serotonin reuptake inhibitors (SSRIs) became present on the 2008 DU90% and was the dominant class of ADs, with sertraline being the most prescribed, followed by escitalopram and paroxetine. APs utilization showed an increasing trend from 2003 until 2018. Atypical APs became present on the 2008 DU90%, while typical APs were no longer included in the 2018 DU90%. Among atypical APs, olanzapine was the main agent prescribed, and starting 2010 was followed by quetiapine and risperidone. The uptake of APs long-acting formulations became more evident during the last analyzed years (2015–2018).Conclusion: We observed an increasing utilization of APs and a more prominent increase in ADs utilization in Romania during 1998–2018. The anxiolytic prescribing remained nearly stable during this time. Further research can bring more information on the various factors influencing psychotropic utilization in Romania.

24 September 2026 in Molecules
Verified
Journal Article
Open access
PDF file
SHSimona Codruța Hegheș
Simona Codruța Hegheș
Oliviu VostinaruOliviu Vostinaru
Oliviu Vostinaru
AAAnamaria Apan
Anamaria Apan
CPCristina Pop
Cristina Pop
IIIrina Iaru
Irina Iaru
LFLorena Filip
Lorena Filip
Phenylpropenes are a significant category of plant volatile compounds that play a crucial role in enhancing the flavor of a variety of herbs and spices. They are a subclass of phenylpropanoid compounds, being important constituents in several plant species like basil, clove, cinnamon, anise, sassafras, nutmeg, and fennel. The most common molecules from the phenylpropene group are represented by anethole, chavicol, cinnamaldehyde, estragole, eugenol, myristicin (methoxy-safrole), and safrole. Beyond their culinary and cosmetic applications, phenylpropenes have been found to have multiple pharmacological effects, including being antimicrobial, antitumoral, antioxidant, anti-inflammatory, antidiabetic, and hypolipemic. This review is focused on the presentation of the latest scientific data resulting mainly from preclinical in vivo and in vitro studies which investigated the pharmacological effects of phenylpropenes, highlighting also the potential health benefits of phenylpropenes in several infectious, inflammatory, cardiovascular, and metabolic diseases. Mechanistic aspects regarding their biological effects and additional safety data are also reviewed.